| 名稱 | Tanespimycin |
| 描述 | Tanespimycin (KOS 953) is an Hsp90 inhibitor (IC50=5 nM) and is selective. Tanespimycin depletes intracellular STK38/NDR1 and decreases STK38 kinase activity. Tanespimycin also downregulated stk38 gene expression. |
| 細(xì)胞實(shí)驗(yàn) | Cells were seeded in 96-well plates at 2,000 cells per well in a final culture volume of 100 μl for 24 h before the addition of increasing concentrations of 17-AAG that was incubated for 5 days. Viable cell number was determined using the Celltiter 96 AQueous Nonradioactive Cell Proliferation Assay. The value of the background absorbance at 490 nm (A490) of wells not containing cells was subtracted. Percentage of viable cells ? (A490 of 17-AAG treated sample/A490 untreated cells) × 100. The IC50 was defined as the concentration that gave rise to 50% viable cell number [1]. |
| 激酶實(shí)驗(yàn) | Purified native Hsp90 protein or cell lysates in lysis buffer (20 mM HEPES, pH 7.3, 1 mM EDTA, 5 mM MgCl2, 100 mM KCl) were incubated with or without 17-AAG for 30 min at 4 °C, and then incubated with biotin-GM linked to streptavidin magnetic beads for 1 h at 4 °C. Tubes were placed on a magnetic rack, and the unbound supernatant removed. The magnetic beads were washed three times in lysis buffer and heated for 5 min at 95 °C in SDS–PAGE sample buffer. Samples were analyzed on SDS protein gels, and western blots done using indicated antibodies. Bands in the western blots were quantified, and the percentage inhibition of binding of Hsp90 to the biotin-GM was calculated. The IC50 reported is the concentration of 17-AAG needed to cause half-maximal inhibition of binding. For in vitro reconstitution, 5 μM of purified Hsp90 was combined with 1 μM each of Hsp70, Hsp40, p23, and Hop purified proteins [1]. |
| 動(dòng)物實(shí)驗(yàn) | B10.BR mice were inoculated with 5×10^5 lymphoma cells through intraperitoneal injection. Seven days following tumor implantation, the mice were I.P. injected with 17-AAG or vehicle (10% DMSO + 40% Cremophor EL: Ethanol (3:1) (v/v) + 50 % PBS) every other day for three weeks. At the cessation of treatment, mice were monitored up to 80 days post tumor cell injection. To determine the effects of 17-AAG on lymphoma initiation in vivo, secondary B10.BR recipient mice were implanted by intraperitoneal injection of 1×10^5 lymphoma cells from the spleens of first-round mice that had been treated with 17-AAG or vehicle. These mice were followed up to 160 days post tumor cell injection to monitor differences in tumor initiation between the mice [4]. |
| 體外活性 | 方法：人A-431、A549、BGC-823、HepG2、HUVEC、L02、MDA-MB-231細(xì)胞用Tanespimycin（0-10 μM）處理72小時(shí)，使用MTT方法檢測(cè)細(xì)胞生長(zhǎng)抑制情況。
結(jié)果：Tanespimycin抑制A-431（IC50=89 nM）、A549（IC50=81 nM）、BGC-823（IC50=847 nM）、HepG2（IC50=91 nM）、HUVEC（IC50=282 nM）、L02（IC50=99 nM）、MDA-MB-231（IC50=0.28 μM）細(xì)胞生長(zhǎng)。[1]
方法： CCA 細(xì)胞用Tanespimycin（0.6 μM）處理72小時(shí)，使用Western Blot方法檢測(cè)靶蛋白表達(dá)水平。
結(jié)果：Tanespimycin下調(diào) Bcl-2、Survivin 和 Cyclin B1，上調(diào) cleaved PARP。[2] |
| 體內(nèi)活性 | 方法：為研究Tanespimycin的抗腫瘤活性，將Tanespimycin（5-40 mg/kg）每隔一天腹腔注射給接種淋巴瘤小鼠，持續(xù)三周。
結(jié)果：Tanespimycin在體內(nèi)抑制淋巴瘤。[3] |
| 存儲(chǔ)條件 | Keep away from direct sunlight,Keep away from moisture,Store at low temperature,
Powder: -20°C for 3 years | In solvent: -80°C for 1 year
Shipping with blue ice/Shipping at ambient temperature. |
| 溶解度 | 10% DMSO+40% PEG300+5% Tween 80+45% Saline : 1 mg/mL (1.71 mM), Sonication is recommended.
DMSO : 50.5 mg/mL (86.22 mM), Sonication is recommended.
|
| 關(guān)鍵字 | tumor | Tanespimycin | stk38 | prostate | NSC-330507 | NSC330507 | Mitophagy | Mitochondrial Autophagy | KOS-953 | KOS953 | Inhibitor | inhibit | HSP90 | HSP | HER2 | Heat shock proteins | CP-127374 | CP127374 | cancer | Bacterial | Autophagy | Apoptosis | Antibiotic | A549 |
| 相關(guān)產(chǎn)品 | Formamide | Guanidine hydrochloride | Aceglutamide | Neomycin sulfate | Terbinafine hydrochloride | Hemin | Dimethyl sulfoxide | Sodium bicarbonate | Hyaluronic acid sodium (MW 20 kDa) | Sodium diacetate | Sulfamethoxazole sodium | D(+)-Raffinose pentahydrate |
| 相關(guān)庫(kù) | 抑制劑庫(kù) | 微生物天然產(chǎn)物庫(kù) | 抗癌活性化合物庫(kù) | 經(jīng)典已知活性庫(kù) | 已知活性化合物庫(kù) | 臨床失敗化合物庫(kù) | 抗衰老化合物庫(kù) | 高選擇性抑制劑庫(kù) | 膜蛋白靶向化合物庫(kù) | 藥物功能重定位化合物庫(kù) | 抗癌臨床化合物庫(kù) | 抗癌藥物庫(kù) |